Skip to Main Content
An official website of the United States government
Epidemiology and Genomics Research Program

Andrea Burnett-Hartman, PhD, MPH

Program Director
Clinical and Translational Epidemiology Branch, Epidemiology and Genomics Research Program


  • PhD – Epidemiology, University of Washington
  • MPH – Epidemiology, University of Michigan
  • BPh – Microbiology and Ecology, Miami University
Contact for questions about:
  • Molecular/genetic epidemiology
  • Risk prediction
  • Precision oncology
  • Health disparities


Andrea Burnett-Hartman, PhD, MPH, is a program director in the Clinical and Translational Epidemiology Branch (CTEB) of the Epidemiology and Genomics Research Program (EGRP) in NCI’s Division of Cancer Control and Population Sciences (DCCPS). She is responsible for managing a research portfolio of grants focused on clinical, lifestyle, and genomic factors that affect cancer outcomes, including those factors that may contribute to observed disparities in health outcomes. Her scientific expertise and interests include cancer epidemiology, early-detection, genetics, risk prediction, health disparities, and precision medicine approaches in cancer care.

Prior to joining NCI, Dr. Burnett-Hartman served for over 15 years as an investigator in multi-site, collaborative research initiatives at the Fred Hutchinson Cancer Center and the Kaiser Permanente Colorado Institute for Health Research. These initiatives included the Population-based Research to Optimize the Screening Process (PROSPR) Consortium, Cancer Research Network (CRN), National Cancer Institute Cohort Initiative (Connect), Kaiser Permanente Research Bank (KPRB), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), and the Patient Outcomes to Advance Learning (PORTAL) Colorectal Cancer Network. She served on the National Leadership Team for a multi-site biobank initiative and is experienced in building research cohorts to study cancer-related outcomes.

Dr. Burnett-Hartman also served on the executive committee, steering committee, and as the scientific lead for the Data Acquisition Unit in the PROSPR-Lung Research Center. Within the CRN, she led the Molecular Markers Workgroup and leveraged this work to lead the Kaiser Permanente Center for Effectiveness and Safety Research initiative to better capture tumor genomic and germline testing and results data from electronic health records to facilitate population-based research in precision medicine. Thus, she has a strong understanding of the use of health system data in research and has been principal investigator or co-investigator on national projects that leverage electronic health records data for cancer research.

Dr. Burnett-Hartman received her Master of Public Health degree from the University of Michigan and completed her doctoral training in epidemiology at the University of Washington. While in Seattle, she completed her post-doctoral training in cancer prevention and molecular epidemiology at the Fred Hutchinson Cancer Center and was a KL2 Scholar in the Institute of Translational Health Sciences at the University of Washington.

Select Publications

Thomas M, Su YR, Rosenthal EA, et al. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations. Nat Commun. 2023;14(1):6147.

Burnett-Hartman AN, Carroll NM, Croswell JM, et al. Percentage up to date with chest computed tomography among those eligible for lung cancer screening. Am J Prev Med. 2023;65(1):126-130.

Steiner JS, Blum-Barnett E, Rolland B, et al. Application of team science best practices to the project management of a large, multi-site lung cancer screening research consortium. J Clin Transl Sci. 2023;7(1):e145.

Burnett-Hartman AN, Lee JK, Demb J, Gupta S. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset colorectal cancer. Gastroenterology. 2021;160(4):1041-1049.

Hua X, Newcomb PA, Chubak J, et al. Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia. Cancer Causes Control. 2020;31(7):631-640.

Burnett-Hartman AN, Newcomb PA, Peters U. Challenges with colorectal cancer family history assessment-motivation to translate polygenic risk scores into practice. Gastroenterology. 2020;158(2):433-435.

Burnett-Hartman AN, Blum-Barnett E, Carroll NM, et al. Return of research-related genetic test results and genetic discrimination concerns: facilitators and barriers of genetic research participation in diverse groups. Public Health Genomics. 2020;23(1-2):59-68.

Burnett-Hartman AN, Chubak J, Hua X, et al. The association between colorectal sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia. Cancer Causes Control. 2019;30(9):979-987.

Burnett-Hartman AN, Udaltsova N, Kushi LH, et al. Clinical molecular marker testing data capture to promote precision medicine research within the Cancer Research Network. JCO Clin Cancer Inform. 2019;3:1-10.

Burnett-Hartman AN, Powers JD, Chubak J, et al. Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network. Cancer Causes Control. 2019;30(7):747-755.

Burnett-Hartman AN, Newcomb PA, Potter JD, et al. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res. 2013;73(9):2863-72.